MEDITECH(SH:603990) Zheng Quan Zhi Xing·2025-06-13 12:00Core Viewpoint - The company, Suzhou Mediston Medical Technology Co., Ltd., has received approval for its non-public issuance of A-shares and is utilizing its own funds to pay for part of the fundraising investment projects, subsequently replacing these with the raised funds in an equal amount [1][2][9] Fundraising Overview - The company issued 19,863,488 shares at a price of 36.63 yuan per share, raising a total of approximately 727.6 million yuan, with a net amount of about 706.6 million yuan after deducting issuance costs [2][3] Fund Utilization - As of May 31, 2025, the company has allocated funds to two main projects: the Regional Emergency and Critical Care Collaborative Rescue System Platform and the Product Service Upgrade Project based on AI technology, with a total intended investment of approximately 733.5 million yuan and 498.4 million yuan already utilized [3][4] Reasons for Using Own Funds - The company faced challenges in directly using raised funds for certain operational expenses such as salaries, social security, and office costs, which necessitated the use of its own funds initially [5][6] Replacement Process - The company plans to replace the amounts paid with raised funds through a structured process, ensuring compliance with regulations and maintaining efficient fund management [6][7] Impact on Company - The use of self-funds for project expenses followed by replacement with raised funds is expected to enhance fund utilization efficiency and reduce financial costs, aligning with the interests of the company and its shareholders [5][9] Approval Procedures - The company’s board and supervisory committee have approved the use of self-funds for project expenses and the subsequent replacement with raised funds, fulfilling necessary procedural requirements [8][9]